A- A A+

For Patients & Visitors

Find a Doctor

Find a Doctor

Dr Andrea Wong

Photo of Dr Andrea Wong
  • Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Department of Oncology - Medical & Radiation, Ng Teng Fong General Hospital
  • ​Assistant Professor, Department of Medicine, NUS Yong Loo Lin School of Medicine
  • Principal Associate Member, Cancer Science Institute
  • Member, Residency Advisory Committee for Medical Oncology
  • Co-Chairman, Clinical Competency Committee, NUHS Medical Oncology Fellowship Programme
  • Management Committee, Haematology-Oncology Research Group
  • Cancer Research Panel, Singapore Cancer Society
MBChB (Hons), MRCP, M Med (Int Med)
Haematology, Medical Oncology
Special Interests:
Early phase clinical trials, Developmental therapeutic - cancer cell metabolism as a therapeutic target
​Principal Investigator and Co-Investigator of multiple clinical trials in the Haematology-Oncology Research Group, National University Cancer Institute, Singapore, NUHS


Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom as well as the National University of Singapore. She specializes in breast and brain cancers and actively contributes to cancer research through her role as an investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS).

She is currently performing translational research work related to the development of novel targeted therapies for the treatment of advanced cancer in her capacity as an Adjunct Research Fellow at the Cancer Science Institute, Singapore. She has received multiple research grants for her work, including the Singapore National Medical Research Council Transition Award in 2018. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the Singapore Society of Oncology.


2018 - 2021: National Medical Research Council (NMRC) Transition Award 
2018: National Medical Research Council (NMRC) Clinican Investigator Salary Support Programme
2017 - 2018: NUHS Clinician Scientist Programme Award
2013 - 2015: National Medical Research Council (NMRC) New Investigator Grant
2012 - 2014: NCIS Centre Grant - Pilot Grant
2010 - 2011: National Medical Research Council (NMRC) Clinican Investigator Salary Support Programme

Journals & Publications

  1. J Li, JQ Eu, LR Kong, L Wang, YC Lim, BC Goh, A Wong. "Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy" Molecules 2020, 25(20), 4831 (IF 3.27)
  2.  A Wong, G Bellot, JL Hirpara, S Pervaiz. "Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer' Biochem Pharmacol (2019) DOI: 10.1016/j.bcp.2019.01.020 (IF 4.82)
  3. N Ngoi, JQ Eu, JL Hirpara, LZ Wang, JSJ Lim, SC Lee,  YC Lim,  S Pervaiz, BC Goh, A Wong. 'Targeting Cell Metabolism as Cancer Therapy' Antioxidants and Redox Signaling (2019) DOI 10.1089/ars.2019.7947 (IF 5.83)
  4. M Lee, J.L. Hirpara, JQ Eu, G. Sethi, Wang L, B.C. Goh, A Wong. 'Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors'. Redox Biol (2018) DOI: 10.1016/j.redox.2018.101073 (IF 7.6)
  5. A Wong, X Xiang, PS Ong, EQY Mitchell, N Syn, I Wee, AP Kumar, WP Yong, G Sethi, BC Goh, P Ho, L Wang. 'A Review on Liquid Chromatography Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.' Pharmaceutics (2018), DOI: 10.3390/pharmaceutics10040221 (IF: 3.9)
  6. A Wong, J.L. Hirpara, S. Pervaiz, J.Q. Eu, G. Sethi & B.C. Goh (2017): Do STAT3 inhibitors have potential in the future for cancer therapy?, Expert Opinion on Investigational Drugs, DOI: 10.1080/13543784.2017.1351941 (IF 5.5)
  7. A Wong, R Sundar, TT Wang, TC Ng, B Zhang, SH Tan, T Soh, A Pang, CS Tan, S Ow, LZ Wang, J Mogro, J Ho, A Jeyasekharan, Y Huang, CH Thng, CW Chan, M Hartman, P Iau, S Buhari, BC Goh, SC Lee. 'Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer' Oncotarget (2016) DOI: 10.18632/oncotarget.11596 (IF 5.1)
  8. A Wong, R Soo, D Tan, SC Lee, J Lim, P Marban, LR Kong, YJ Lee, LZ Wang, WL Thuya, R Soong, MQ Yee, TM Chin, MT Cordero, BR Asuncion, B Pang, S Pervaiz, JL Hirpara, A Sinha, WW Xu, M Yuasa, T Tsunoda, M Motoyama, T Yamauchi, BC Goh, 'Phase I and Biomarker Study of OPB-51602, a Novel Signal Transducer and Activator of Transcription (STAT) 3 Inhibitor, in Patients with Refractory Solid Malignancies'. Annals of Oncology (2015), 26 (5): 998-1005. (IF 11.8)
  9. Y Bao, G Oguz, WC Lee, PL Lee, K Ghosh, J Li, P Wang, P Lobie, H Ditzel, A Wong, EY Tan, SC Lee, and Q Yu. "EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy" Nat Comms (2020), 11: 5878 (IF 11.8)
  10. V Heong, D Tay, S Goh, B Wee, TZ Tan,R Soo, B Pang, D Lim, A Gopinathan, S Ow, CE
    Chee, BC Goh, SC Lee, WP Yong, A Wong, R Soong, D Tan 'Whole exome sequencing of multi-regional biopsies from metastatic lesions to evaluate actionable truncal mutations using a single-pass percutaneous technique' Cancers (2020) Article cancers-791356 (IF 6.1)
  11. EH Tan, A Wong, CC Tan, P Wong, SH Tan, Y Ang, SE Lim, WQ Chong, JS Ho, SC Lee, BC Tai "Improving Medication Adherence with Adjuvant Aromatase Inhibitor in Women with Breast Cancer: A Randomised Controlled Trial to Evaluate the Effect of Short Message Service (SMS) Reminder" The Breast (2020) DOI: 10.1016/j.breast.2020.06.012 (IF 2.38)
  12. N Syn, A Wong, SC Lee, HL Teoh, J Uip, R Seey, WT Yeo, W Kristanto, PC Bee, LM Poon, P Marban, TS Wu, M Winther, L Brunham, R Soon, BC Tai, BC Goh. 'Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial' BMC Medicine (2018) DOI: 10.1186/s12916-018-1093-8 (IF 9.0)
  13. JL Hirpara, JQ Eu, JKM Tan, A Wong, M Clement, L Kong, N Ohi, T Tsunoda, J Qu, BC Goh, S Pervaiz. 'Metabolic Reprogramming of Oncogene-Addicted Cancer Cells to OXPHOS as a Mechanism of Drug Resistance' Redox Biol (2018) DOI: 10.106/j.redox.2018.101076 (IF: 7.6) [Winner of the Swee Liew-Wadsworth Research Publication Silver Award 2019]

Professional Memberships

American Society of Clinical Oncology
Singapore Society of Oncology